2021
Corticosteroid use in chronic dermatologic disorders and osteoporosis
Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal Of Women's Dermatology 2021, 7: 545-551. PMID: 35024411, PMCID: PMC8721058, DOI: 10.1016/j.ijwd.2021.07.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGlucocorticoid-induced osteoporosisGlucocorticoid therapyChronic dermatologic disordersUse of glucocorticoidsSerious side effectsGlucocorticoid useCorticosteroid useBone healthBone lossDermatologic disordersSide effectsPatientsOsteoporosisGlucocorticoidsTherapyCase vignettesRiskComplicationsDermatologistsDiabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome
Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.ChaptersHyperosmolar hyperglycemic syndromeDiabetic ketoacidosisAcute complicationsHyperglycemic syndromeAnion gap metabolic acidosisSerious acute complicationsGap metabolic acidosisAppropriate clinical careImmediate medical attentionMetabolic acidosisExtreme hyperglycemiaMedical attentionClinical careSevere dehydrationHealthcare providersPatientsKetoacidosisComplicationsHyperglycemiaSyndromeDiabetesKetonemiaPathophysiologyAcidosisDiagnosis
2018
Diabetes medications and cardiovascular disease
Lupsa BC, Inzucchi SE. Diabetes medications and cardiovascular disease. Current Opinion In Endocrinology Diabetes And Obesity 2018, 25: 87-93. PMID: 29369916, DOI: 10.1097/med.0000000000000400.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitus patientsPeptide-1 receptor agonistsGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetes mellitus patientsType 2 diabetesCause of mortalityCardiovascular complicationsCardiovascular outcomesDiabetes medicationsMicrovascular complicationsCardiovascular effectsMellitus patientsReceptor agonistDrug categoriesIntensive controlDiseaseComplicationsMedicationsClear benefitRecent studiesSignificant improvement
2013
Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome
Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2013, 15-31. DOI: 10.1007/978-1-62703-697-9_2.ChaptersHyperosmolar hyperglycemic syndromeDiabetic ketoacidosisAcute complicationsHyperglycemic syndromeAnion gap metabolic acidosisSerious acute complicationsGap metabolic acidosisAppropriate clinical careImmediate medical attentionMetabolic acidosisExtreme hyperglycemiaMedical attentionClinical careSevere dehydrationHealthcare providersPatientsKetoacidosisComplicationsHyperglycemiaSyndromeDiabetesKetonemiaPathophysiologyAcidosisDiagnosis